A senior executive in one of the world's leading pharmaceutical companies has called the Health Service Executive's delay in approving its stroke medication for reimbursement as "quite frankly unacceptable".
John Dixon, managing director of Boehringer Ingelheim UK and Ireland, told *The Sunday Business Post* that no other country had "such a cumbersome and delaying process" for approval.
It took almost a year for the HSE to approve Pradaxa for reimbursement under the public healthcare system....
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team